Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Study Overview
=================
Brief Summary
-----------------
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

Detailed Description
-----------------
This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed informed consent, patients will be screened for entry into the study. The study will be conducted in 2 stages: dose escalation in Part A of the study (Phase I) followed by dose expansion in Part B (Phase IIA). Escalation cohorts will receive repeat doses of CB-103 to determine the MTD and RP2D. CB-103 will be administered orally in treatment cycles of 28-days each. Aim of the expansion Phase IIA, Part B of the study will be to collect preliminary evidence of anti-tumour activity.

Official Title
-----------------
A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway

Conditions
-----------------
Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL

Intervention / Treatment
-----------------
* Drug: CB-103


Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Disease Patients with histologically or cytologically confirmed solid tumours (breast cancer (triple negative breast cancer [TNBC], ER+/-, HER2+/-), gastrointestinal (GI) cancers (resistant to oxaliplatin or irinotecan-based therapy colorectal cancer [CRC]), osteosarcoma, adenoid cystic carcinoma (ACC), and malignant glomus tumour) that are surgically unresectable, locally advanced, or metastatic and whose disease has progressed on at least one line of systemic therapy (with the exception of ACC patients who are allowed to be systemic treatment-naïve) and for whom no established therapeutic alternatives exist. Any other solid cancer (including lymphoma) with a confirmed NOTCH1-4 activating mutation or genetic lesion. Relapsed or refractory (r/r) T-cell acute lymphoblastic leukaemia (T-ALL) or lymphoma (T-LBL) with a confirmed NOTCH pathway activation. Refractory patients are defined as T-ALL/T-LBL patients with ≥ 5% bone marrow blasts, and/or concomitant extramedullary involvement, who have not achieved a CR after standard induction/consolidation therapy attempt. Demography: men and women ≥ 18 years old Adequate organ function and laboratory results Adequate contraceptive measures Signed informed consent EXCLUSION CRITERIA Medical History Patients with symptomatic CNS metastases (neurologically unstable or requiring increasing doses of steroids to control their CNS disease) Hypersensitivity to any of the excipients of CB-103 Patients with unresolved nausea, vomiting, or diarrhoea of CTCAE grade > 1 Impairment of GI function or presence of GI disease that may significantly alter the absorption of CB-103 History of second or other primary cancer with the exception of: Curatively treated non-melanomatous skin cancer Curatively treated cervical cancer or breast carcinoma in situ Other primary solid tumour treated with curative intent and no known active disease present and no treatment administered during the last 2 years. Exclusionary concurrent medical conditions Impaired cardiac function or clinically significant cardiac diseases. Prior Therapy In patients with solid tumours cytotoxic chemotherapy within 3 weeks In T-ALL/T-LBL patients, prior anticancer therapy less than 2 weeks prior to starting therapy or 5 half-lives (whichever is longer) with exceptions. Radiation therapy within 2 weeks of scheduled CB-103 dosing day 1 Immunotherapy, biological therapies, targeted small molecules, hormonal therapies within 3 weeks of scheduled CB-103 dosing day 1 Unresolved toxicity CTCAE grade > 1 from previous anti-cancer therapy or radiotherapy (excluding neurotoxicity, alopecia, ototoxicity, lymphopenia), or incomplete recovery from previous surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CB-103<br>CB-103 capsules will be administered orally in treatment cycles of 28-days each. | Drug: CB-103<br>* Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part A: Dose limiting toxicity (DLT) | Number of patients with dose limiting toxicity | 28 days | 
| Part B: antitumour efficacy | Best overall response rates of each tumor type using appropriate response Evaluation Criteria | up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part A and B: incidence of all adverse events and serious adverse events (safety and tolerability) | Number of participants with adverse events as a measure of safety and tolerability | up to 12 months | 
| Part A and B: pharmacokinetic - Cmax | Maximum plasma concentration | PK profiling in cycle 1 and 2 (cycle duration: 28 days) | 
| Part A and B: pharmacokinetic - tmax | Time to Cmax | PK profiling in cycle 1 and 2 (cycle duration: 28 days) | 
| Part A and B: pharmacokinetic - AUC | Area under the curve during 8 and 24 hours | PK profiling in cycle 1 and 2 (cycle duration: 28 days) | 
| Part A and B: pharmacokinetic - t1/2 | elimination half-life | PK profiling in cycle 1 and 2 (cycle duration: 28 days) | 
| Part A: preliminary antitumour efficacy | Overall response rates of each tumor type using appropriate response evaluation criteria | up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
advanced solid tumours, haematological malignancies, phase I/II, NOTCH pathway, pan-NOTCH inhibitor